Therapeutic effect of DPP-4 inhibitors, which are approved to treat diabetes, on improving prognosis of post-operative colorectal cancer patients
Description: Objectives: To investigate the therapeutic potential of DPP4 inhibitors in post-operative CRC patients.
Hypothesis to be tested:
1. CRC patients treated with DPP4-inhibitors have a better prognosis compared to those not treated with DPP4-inhibitors.
2. Immune cell profile is altered by DPP4-inhibitors and is the potential mechanism of DPP4-inhibitor regulated antitumor effect. It is a potential biomarker for identifying candidates for DPP4-inhibitor treatment
3. DPP4-inhibitors improve the prognosis of post-operative subject in immunocompetent mouse model.
Design and subjects:
This is a two stage study. In the first stage, we will retrospectively retrieve the patient record during 2006 to 2018 for colorectal cancer patients prescribed with DPP4-inhibitors and compare their prognosis with control group (Metformin). The immune cell profile and association with DPP4-inhibitor and prognosis will also be compared.
In the second stage, we will apply immunocompetent mouse model and synergeneic mouse colon cancer cell-line to investigate the effect of DPP4-inhibitors on improving prognosis of post-operative mouse.
Instruments: NA
Interventions: NA
Main outcome measures: Prognosis (Disease-free and overall survival) data, hazard ratio.
Data analysis: The survival data and recurrence rate will be compared between post-operative CRC patients (for stage 1) and mice (for stage 2) treated and not treated with DPP4-inhibitor. Immune cell profile will be compared between good and poor prognosis group upon DPP4-inhibtor treatment.
Expected results:
It is expected that this study can demonstrate the efficacy of DPP4-inhibitors in treating post-operative CRC patients, or a subgroup of CRC patients (such as those with diabetes comorbidity).
Funder: Health and Medical Research Fund
Amount: HKD 977,000
Funding type: grant
Funder scheme: HMRF - Advanced Medical Research
Start date: 2019-01-01
Investigator: Wai Lun LAW (lead)
Institutions: University of Hong Kong, Department of Surgery, The University of Hong Kong
Subfield: Molecular Biology
Domain: Life Sciences
Funded outputs count: 2
Funder award ID: 08193116
OpenAlex ID: G5607042437
